Investigating Cellular Senescence at the Single Cell Level
- Institution
- UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT
- Principal investigator
- Rachel Cohn
- Funding
- $55K
- Duration
- 2023–2026
Moonbase score
Still being scored
Abstract
Project Summary/Abstract Aging is a key risk factor for chronic disease development which can affect lifespan and quality of life. Cellular senescence has emerged as a potential target to slow down the aging process. Senescent cells are in a state of proliferative arrest and are highly associated with aging and pathological conditions. They accumulate in multiple tissues and secrete pro-inflammatory cytokines and other kinds of molecules that damage surrounding tissues. The markers p16 and p21 (cyclin dependent kinase inhibitors) are commonly used to identify senescent cells, but emerging evidence has shown that these markers are not entirely sensitive or specific markers for senescence. There is currently a lack of understanding of the exact genetic markers that define senescent cells especially on the single cell level. With studies showing that senescent cell clearance can alleviate various diseases associated with aging it is vital to achieve a greater understanding of senescent cell markers so that precision medicine treatments can be designed to more effectively eliminate senescent cells. In this proposal we aim to examine the transcriptome of senescent cells on the single cell level both with aging and senolytic treatment in human adipose tissues. Senescent cells have been demonstrated to accumulate in adipose tissue with aging and chronic disease and with the vast array of cell types present in adipose tissue it makes an excellent model to study specific cell types and markers associated with senescence. Aim 1 will explore the transcriptome of naturally occurring senescent cell populations in adipose tissue with aging. We will use single nucleus RNA sequencing to capture cell types sensitive to typical single cell dissociation methods and compare the transcriptome differences between cells in aged vs. young tissues. We hypothesize that adipose tissue from older donors will contain more senescent cells and that several novel genetic markers will be identified in these cells. Aim 2 will look at the effects of senolytic treatment on human adipose tissue on the single cell level. Senolytics are drugs that are designed to specifically eliminate senescent cells but we do not know the precise cell types targeted by senolytics. We will use single nucleus RNA sequencing to uncover the transcriptome changes that occur with senescent cell elimination and learn what cell types are removed with senolytic treatment. This project will help advance the field achieving a greater understanding of senescent cell populations in adipose tissue and the markers that define them, which is essential to understanding and potentially treating numerous diseases. Through this fellowship my training will include developing my skills in genetics, aging, computational analysis, communication, presentation, networking, scientific writing, clinical knowledge and mentorship. This training will occur in the environment of UCONN Health as well as the Jackson Laboratory and other research institutions. This work will allow me to take advantage of training opportunities and mentorship to advance my career as a future physician-scientist.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Connecticut Sch of Med/Dnt64
Molecular Mechanisms of Pseudomonas aeruginosa Antibiotic Persistence in Monocultures and Microbial Communities
Patricia Jin Hare · $58K · 2023–2027
- NIH · University of Connecticut Sch of Med/Dnt63
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
Margaret Kathleen Callahan · $553K · 2023–2028
- NIH · University of Connecticut Sch of Med/Dnt55
Causative mechanisms for keloid formation
Ernst J Reichenberger · $422K · 2024–2028